Trials / Completed
CompletedNCT03015220
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 458 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD). |
| DRUG | Dulaglutide | Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD). |
Timeline
- Start date
- 2017-01-10
- Primary completion
- 2018-07-12
- Completion
- 2018-07-12
- First posted
- 2017-01-09
- Last updated
- 2021-03-02
- Results posted
- 2019-12-30
Locations
34 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03015220. Inclusion in this directory is not an endorsement.